MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$4,690K
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-02-28
2025-11-30
2025-08-31
General and administrative
1,654
1,799
1,713
Research and development
4,649
3,302
3,232
Legal settlement loss
-
16,587
-
Total operating expenses
6,303
21,688
4,945
Operating (loss) gain
-6,303
-21,688
-4,945
Interest income
15
57
94
Interest on convertible notes
614
644
676
Issuance costs for private placement of shares and warrants through placement agent (note 5)
1,628
-
-
Standby equity purchase agreement commitment fee
-
325
-
Legal settlement revaluation
3,842
-
-
Finance charges
2
7
13
Total interest and other expenses
1,613
-919
-595
(loss) gain before income taxes
-4,690
-22,607
-5,540
Income tax benefit
0
0
0
Net (loss) income
-4,690
-22,607
-5,540
Basic EPS
0
-0.02
0
Diluted EPS
0
-0.02
0
Basic Average Shares
1,275,184,000
1,261,016,000
1,252,551,000
Diluted Average Shares
1,275,184,000
1,261,016,000
1,252,551,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net (loss) income
-$4,690K
Legal settlement
revaluation
$3,842K
Interest income
$15K
(loss) gain before
income taxes
-$4,690K
Total interest and
other expenses
$1,613K
Issuance costs for
private placement of...
$1,628K
Interest on convertible
notes
$614K
Finance charges
$2K
Operating (loss) gain
-$6,303K
Total operating
expenses
$6,303K
Research and development
$4,649K
General and
administrative
$1,654K
Buy us a coffee
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)